RayBiotech , the antibody array specialist, have just released a new, very broad antibody microarray, the L2000 series, for the profiling of 2000 protein targets including metabolic enzymes, structural proteins, and a variety of cytokines, growth factors, proteases, and signaling proteins. Based on the same technology as the “smaller” version L1000, the L2000 array is the quickest and simplest method to profile extensive protein expression with small sample volume. In this post, we’ll look at the array’s features and technology, as well as the possibility to outsource your profiling project to experts in Europe, particularly for one shot experiments, to save you the time to set up the technology in your lab whilst securing the quality of your data.

Whether you wish to perform protein expression profiling for biomarker validation, are deciphering a disease physio-pathology, are looking for the right target to study the effect of your compounds or keen to check what its mechanism of action may be, it’s not always easy to decide on the best tool to choose. I have selected a few solutions below that may bring some quick answers to these questions, and help you move faster to the next step of your biomarker project: they’re either quick to implement in your own lab or easily outsourced at a reasonable cost in a European partner platform.

In a previous post, I introduced the C-series multiplex profiling technology from Raybiotech, a smart way to multiplex your western blot while saving time and sample volume, and decreasing the cost of your experiment.

Indeed, one blot for multiple targets processed at once is a nice way to boost your protein profiling studies!

I just wanted to highlight in this post, that on top of the standard species models like human, mouse and rat, these C-series are also available for many other models. With 15 different species to select from, RayBiotech is leading the way for immunoassay kit species diversity.

Immune checkpoint molecules play an important role in T cell functionality after TCR/MHC signalling. Blockade of two B7/CD28 family checkpoint molecules, CTLA-4 and PD-1, have already demonstrated excellent efficacy in increasing T cell responses to a variety of tumours. Identification of novel target and new checkpoint blockade remains a key element in Drug Discovery (See “Drug discovery: Immunotherapy checkpoint research for new Cancer treatments“). In this post, let’s take a look at the “Quantibody® Human Immune Checkpoint Molecule Array 1” for the detection of 10 Human Immune Checkpoint biomarkers.